We report the successful treatment of the patient with osimertinib 80 mg/day following disease progression and a discordance in the detection of a mechanism of resistance epithelial growth factor receptor (EGFR) T790 M between liquid biopsy and tissue biopsy methods. | Effective osimertinib treatment in a patient with discordant T790 M mutation detection between liquid biopsy and tissue biopsy